🔎 Trials Near Me

Home › Epithelial Carcinoma ng Ovary › Tennessee

Pag-aaral pangklinika para sa Epithelial Carcinoma ng Ovary sa Tennessee

6 pag-aaral para sa Epithelial Carcinoma ng Ovary ang naghahanap ng mga kalahok sa mga site sa Tennessee.

Mga Lungsod sa Tennessee

Opisyal na teksto ng pag-aaral (English)

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Erlanger Health, Chattanooga
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Okt 5, 2026 · NCT06915025

Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer

  • University of Tennessee Medical Center - Knoxville, Knoxville
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Kababaihan · Na-update Ago 17, 2026 · NCT07764133

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  • Research Site, Germantown
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 21, 2026 · NCT07218809

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Sarah Cannon Research Institute (Oncology Associates of Oregon PC), Nashville
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 2, 2026 · NCT06819007

CT-95 in Advanced Cancers Associated With Mesothelin Expression

  • Context Investigational Site, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT06756035

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  • Vanderbilt University Medical Center, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 15, 2025 · NCT04429542

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.